Rahul D. Ballal, Director at Enliven Therapeutics, Inc. (ELVN), sold 26,556 shares at $19.16 ($509K) on 2024-03-20, disclosed to the SEC on 2024-03-22.
Scheduled sale ($509k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.16 | 13,278 | $254K | 50.0% |
| 2 | $19.16 | 13,278 | $254K | 50.0% |
| Total | $19.16 avg | 26,556 | $509K | 100% |
| Filing → |
| ELVN | SELL | 2024-04-12 | $1.6M | — | Filing → |
| ELVN | SELL | 2024-04-08 | $133K | — | Filing → |
| ELVN | SELL | 2024-04-03 | $124K | — | Filing → |